Printer Friendly

NEWVISION ANNOUNCES PURCHASE AND START UP OF LASER REFRACTIVE SURGERY CENTERS IN THE UNITED KINGDOM

 BURLINGTON, Mass., June 29 /PRNewswire/ -- Stephen M. Blinn, recently appointed executive vice president and chief operating officer of NewVision Technology (NASDAQ: VISN) announced today NewVision has finalized the purchase of two existing laser refractive surgery centers presently operating in BUPA hospitals within the United Kingdom. These two centers have treated hundreds of patients with refractive disorders and are now processing thousands of patient inquiries to select out additional treatment candidates. Revenue to NewVision from these centers will be phased in over the next few months.
 Also announced was the first installation of a refractive laser in a joint BUPA/NewVision center. Blinn stated, "This is the first of at least eight new laser refractive surgery centers which NewVision plans to complete pursuant to our joint venture agreement with BUPA. NewVision expects to be the leading provider of laser refractive correction throughout the United Kingdom by the end of 1993. The United Kingdom represents approximately one fourth of the potential United States market for laser refractive correction; leadership in that market is an ambitious goal for NewVision. We see these present developments as a solid foundation for NewVision's larger strategic objectives within the ever-expanding laser refractive correction industry."
 BUPA, with 1992 revenues exceeding $1.6 billion, is the largest provider of private health care in the U.K. It presently owns and operates 89 healthcare facilities throughout England, Scotland, Wales and Northern Ireland. The purchases and installation are part of a previously announced agreement which provides for the establishment of a minimum of 10 BUPA/NewVision laser refractive surgery centers within the next 12 months.
 The BUPA/NewVision centers will utilize excimer lasers and a technique called photorefractive keratectomy (PRK) to correct common vision disorders such as nearsightedness, farsightedness and astigmatism now being treated with eyeglasses and contact lenses. Within the U.K., these conditions are estimated to affect more than 30 million people and presently account for in excess of $1.2 billion in annual corrective eye wear purchases and related examinations.
 At a BUPA/NewVision laser refractive surgery center, certain wearers of eyeglasses or contact lenses may be candidates to have their vision disorder corrected in an outpatient procedure. Utilizing a computer assisted excimer laser, an ophthalmologist can remove a minute layer of tissue from the front surface of the eye to make it optically correct.
 The business of New Vision Technology, Inc. is to provide to its customers and partners in the ophthalmic community the safest and most efficacious technologies and techniques, coupled with sophisticated marketing and promotional support, for the correction of common vision disorders and to share in the revenge generated thereby.
 For further information contact investor relations at 617-229-1100.
 -0- 6/29/93
 /CONTACT: Lillian Boyle of NewVision Technology, 617-229-1100/
 (VISN)


CO: NewVision Technology ST: Massachusetts IN: MTC SU:

DJ -- NE008 -- 6729 06/29/93 13:12 EDT
COPYRIGHT 1993 PR Newswire Association LLC
No portion of this article can be reproduced without the express written permission from the copyright holder.
Copyright 1993 Gale, Cengage Learning. All rights reserved.

Article Details
Printer friendly Cite/link Email Feedback
Publication:PR Newswire
Date:Jun 29, 1993
Words:473
Previous Article:TWA ACCEPTS FIRST OF SIX NEW MD-80 TWIN JETS
Next Article:BAXTER DIAGNOSTICS INC., ENTERS INTO STRATEGIC CARDIAC DIAGNOSTIC ALLIANCE WITH SPECTRAL DIAGNOSTICS INC. AND PLANS FOR EQUITY INVESTMENT
Topics:


Related Articles
SUMMIT TECHNOLOGY ANNOUNCES FDA APPROVAL TO BEGIN SECOND PHASE OF U.S. CLINICAL TRIALS USING HOLMIUM LASER FOR TREATMENT OF FARSIGHTEDNESS
SUMMIT TECHNOLOGY ANNOUNCES FDA APPROVAL TO BEGIN SECOND PHASE OF U.S. CLINICAL TRIALS USING HOLMIUM LASER FOR TREATMENT OF FARSIGHTEDNESS
ISL SHIPS TWO EYE LASER SYSTEMS FOR TREATMENT OF MYOPIA AND HYPEROPIA TO ITALY
NEWVISION ANNOUNCES EXPANSION OF ITS EXCIMER LASER SURGERY CENTERS NETWORK INTO CARDIFF, WALES AND LONDON, ENGLAND
NEWVISION TECHNOLOGY, INC. ANNOUNCES THE APPOINTMENT OF MYRON YANOFF, M.D. TO ITS ADVISORY BOARD
Excimer Laser Surgery to Correct Astigmatism Approved for U.S. Market
NIDEK GETS 510(K) CLEARANCE FOR MK-2000 KERATOME SYSTEM.
LaserSight Expands Relationship With Becton Dickinson For Keratome Product Distribution.
LaserSight Comments on AAO Meeting.
Nidek Granted U.S. Patent for Cross-Cylinder Ablation; Nidek Develops New Method for Treating Astigmatisms Using LASIK Technology.

Terms of use | Copyright © 2016 Farlex, Inc. | Feedback | For webmasters